Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease. (February 2018)

• Record Type: Journal Article
• Authors: Kusters, Cynthia D.J.; Paul, Kimberly C.; Guella, Ilaria; Bronstein, Jeff M.; Sinsheimer, Janet S.; Farrer, Matt J.; Ritz, Beate R.
• Is Part Of: Parkinsonism & related disorders. Volume 47(2018)
• Page Start: 39
• Page End: 44
• Publication Date: 2018-02
• Subjects: Parkinson's disease -- Dyskinesia -- DRD1-3 and BDNF genes -- Haplotypes; Parkinson's disease -- Periodicals; Movement disorders -- Periodicals; Movement Disorders -- Periodicals; Nerve Degeneration -- Periodicals; Nervous System Diseases -- Periodicals; Parkinson Disease -- Periodicals; Tremor -- Periodicals; Parkinson, Maladie de -- Périodiques; Parkinson's disease; 616.833
• DOI: 10.1016/j.parkreldis.2017.11.339
• Languages: English
• ISSNs: 1353-8020

Abstract

Abstract: Objective: Dyskinesia is a known side-effect of the treatment of Parkinson's Disease (PD). We examined the influence of haplotypes in three dopamine receptors ( DRD1, DRD2 and DRD3 ) and the Brain Derived Neurotrophic Factor ( BDNF ) on dyskinesia. Methods: Patient data were drawn from a population-based case-control study. We included 418 patients with confirmed diagnoses by movement disorder specialists, using levodopa and a minimum three years disease duration at the time of assessment. Applying Haploview and Phase, we created haploblocks for DRD1-3 and BDNF. Risk scores for DRD2 and DRD3 were generated. We calculated risk ratios using Poisson regression with robust error variance. Results: There was no difference in dyskinesia prevalence among carriers of various haplotypes in DRD1. H owever, one haplotype in each DRD2 haploblocks was associated with a 29 to 50% increase in dyskinesia risk. For each unit increase in risk score, we observed a 16% increase in dyskinesia risk for DRD2 (95%CI: 1.05–1.29) and a 17% (95%CI: 0.99–1.40) increase for DRD3 . The BDNF haploblock was not associated, but the minor allele of the rs6265 SNP was associated with dyskinesia (adjusted RR 1.31 (95%CI: 1.01–1.70)). Conclusion: Carriers of DRD2 risk haplotypes and possibly the BDNF variants rs6265 and DRD3 haplotypes, were at increased risk of dyskinesia, suggesting that these genes may be involved in dyskinesia related pathomechanisms. PD patients with these genetic variants might be prime candidates for treatments aiming to prevent or delay the onset of dyskinesia. Highlights: DRD genes (DRD1-3) and BDNF have been proposed to be involved in the development of dyskinesia. DRD2 haplotypes, and potentially DRD3 haplotypes and rs6265 BDNF -SNP, were associated with dyskinesia. Patients with these genetic markers appear prime candidate for testing approaches to prevent or delay dyskinesia development.